Drug intelligence / Profile preview

CVL-047

Development stage: Preclinical
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

CVL-047 is a **selective phosphodiesterase type 4 (PDE4) inhibitor** that is PDE4D-sparing, meaning it does not inhibit the PDE4D subtype, which is believed to contribute to gastrointestinal side effects observed with other PDE4 inhibitors. It is being developed for the **treatment of major depressive disorder (MDD) and schizophrenia**. The drug is designed with the intent to target neurological disorders with improved side effect profiles, leveraging modern drug discovery platforms including artificial intelligence and DNA-encoded chemical libraries.[1][4][7]

Targets

PDE4APDE4C (Phosphodiesterase 4C)PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)

Beyond the preview

Go deeper on CVL-047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVL-047.

Explore the full profile